Akero治疗药物EFX显示,在MASH患者中扭转肝病的前景良好。 Akero Therapeutics' drug EFX shows promise in reversing liver disease in patients with MASH.

Akero治疗学已经揭示出其HARMONY研究的可喜结果,表明efruxifermin(EFX)可以扭转肝前代谢机能障碍 -- -- 与胃炎有关的类肝炎(MASH)患者的病症。 Akero Therapeutics has revealed promising results from its HARMONY study, showing that efruxifermin (EFX) can reverse disease in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). 96周后,40%以上接受EFX 50mg治疗的病人显示,纤维化情况有所改善,肝脏健康标记得到改善,而安慰剂患者的比例为0%。 After 96 weeks, more than 40% of patients treated with EFX 50mg showed improved fibrosis and better liver health markers, compared to 0% on placebo. 该药物还导致50%以上接受治疗的病人肝硬度和纤维化生物标记在临床上减少。 The drug also led to clinically meaningful reductions in liver stiffness and fibrosis biomarkers in over 50% of treated patients. 这些调查结果表明,EFX可以成为对MASH的一个重要的新疗法。 These findings suggest EFX could be a significant new therapy for MASH.